OmniAb ended 2025 with 32 active clinical programs from its OmnidAb single-domain platform in human testing and expects multiple new entries in 2026. Management reports $350 million in remaining contracted milestone payments for active programs and over $3 billion in total committed milestones across 407 programs, with an average 3.4% royalty rate.

Fourth-quarter 2025 revenue declined to $8.4 million from $10.8 million year-over-year, driven by lower license revenue, offset partially by increased milestone and royalty revenues. Operating expenses fell to $24.1 million from $26.7 million, reflecting lower personnel and service costs; net loss widened to $14.2 million, or $0.11 per share.

In mid-December, OmniAb launched OmniUltra, a transgenic chicken platform designed for ultra-long CDRH3 human antibodies, with three initial partner programs at launch and growing interest in picobody applications. Additionally, the xPloration Partner Access program deployed two instruments by year-end, offering in-lab single B-cell screening and potential software subscription revenue.

OmniAb added 84 new programs in 2025 despite 40 terminations, ending the year with 107 partners running 407 active programs. Near-term events include top-line data from Immunovant’s IMVT-1402 rheumatoid arthritis trial, two phase III batoclimab studies, and milestone-triggering results from Teva and Merck KGaA collaborations.